U.K.-based Boots pharmacy

According to a report, Walgreens is putting advisors in place, including Goldman Sachs, to explore options for Boots.

Target showcases new store designs

In 2021 Target opened 32 new locations, including 28 small-format stores.

BJís Wholesale Club to open Pittsburgh

Located in Pennsylvaniaís South Fayette Township, this new club will be the retailerís first in the Pittsburgh market, the company said. BJís Wholesale Club is opening a brand-new club in Pennsylvania.

CVS Health, Microsoft ink deal to redefine personalized care

CVS Health, Microsoft ink deal to redefine personalized care CVS Health and Microsoft are joining forces to create innovative solutions to help consumers improve their health. CVS Health is embarking on a brand-new partnership with Microsoft.

New Facebook Policy Requires Certification and Pre-Approval for Telemedicine Company Advertisements

Social Media is Cracking Down on Business Models Certain business models will now be required to obtain a specific certification called LegitScript in order to advertise on social media. Online pharmacies, telemedicine providers and pharmaceutical manufacturers that are LegitScript-certified will be the only categories with pre-approval. Advertising of pharmaceuticals has been strict for quite a while already and now it just got stricter.

FDA panel rejects Pfizer arthritis drug as too risky

An FDA advisory panel recommended Thursday, in a vote of 19-1, against approving Pfizer's experimental drug for the treatment of mild to moderate knee and hip pain.

Jazz Pharmaceuticals gets FDA nod for new indication of Vyxeos

Zacks Equity Research March 31, 2021∑4 min read Jazz Pharmaceuticals plc JAZZ announced that the FDA has granted approval to label expansion of its leukemia drug, Vyxeos, in pediatric patients aged one to 21 years. The drug is now approved to treat adult as well as paediatric patients with newly-diagnosed therapy-related acute myeloid leukemia (t-AML) or AML with myelodysplasia-related changes (AML-MRC).

FDA Approves First Cell-Based Gene Therapy for Adult Patients with Multiple Myeloma

The U.S. Food and Drug Administration approved Abecma (idecabtagene vicleucel), a cell-based gene therapy to treat adult patients with multiple myeloma who have not responded to, or whose disease has returned after, at least four prior lines (different types) of therapy. Abecma is the first cell-based gene therapy approved by the FDA for the treatment of multiple myeloma.

Type in the code you see below.